Sayad Pierre Sargis 4

What Happened

• Sayad Pierre Sargis, Chief Medical Officer of Fennec Pharmaceuticals (FENC), exercised/converted a derivative on 2026-04-30 that resulted in the acquisition of 168 shares of common stock at $0.00 per share (total cash paid $0).
• The filing notes these shares were released from restriction from an award granted on 2025-03-28, indicating this was a conversion/vesting of a previously granted award rather than an open-market purchase.

Key Details

• Transaction date: 2026-04-30; filed with the SEC on 2026-05-01 (timely filing).
• Transaction type/code: M (exercise or conversion of derivative).
• Shares acquired: 168; price per share: $0.00; total cash paid: $0.
• Footnote: F1 — "Represents shares released from restriction from shares awarded 3/28/2025."
• Shares owned after transaction: not specified in the provided filing.

Context

• This was a conversion/vesting event (derivative-to-common-stock) tied to a prior award; no shares were sold in connection with this transaction and no cash changed hands.
• Such conversions/vestings are typically part of compensation or incentive awards and are routine corporate insider events; they do not necessarily indicate new buying or selling intent.